Judith S. Hochman, MD

About Me

Conditions and Treatments

acute coronary syndrome, coronary heart disease, heart attack


  • Harold Snyder Family Professor of Cardiology, Department of Medicine
  • Assoc Dir Leon H Charney Div of Cardiology
  • Sr Assoc Dean for Clinical Sciences
  • Dir Cardiovascular Clinical Research Center
  • Co Dir Clinical and Translational Science Inst
Board Certifications
  • American Board of Internal Medicine (Cardiovascular Disease), 1983
  • American Board of Internal Medicine - Internal Medicine, 1980
Education and Training
  • Fellowship, Johns Hopkins Hospital, Medicine/Cardiology, 1982
  • Residency, Peter Bent Brigham Hospital, Medicine, 1980
  • MD from Harvard University, 1977

Locations and Appointments

550 1st Avenue
New York, NY 10016


Phone: 212-263-6927

Welcome back!

As a returning patient for this doctor, please schedule an appointment using your MyChart at NYU Langone account.

Learn more about MyChart at NYU Langone.

My Research

Dr. Hochman directs the Cardiovascular Clinical Research Center (CCRC)[http://medicine.med.nyu.edu/cardiology/cardiovascular-clinical-research-center-ccrc] at the New York University School of Medicine and serves as Co-Director of the NYU-HHC Clinical and Translational Science Institute. Her particular areas of interest include the management of ischemic heart disease, both acute and chronic, with a special interest in the role of revascularization with either PCI or CABG, and the pathophysiology and management of cardiogenic shock. She is currently the Study Chair of the ISCHEMIA Trial, an NHLBI/NIH funded multicenter randomized clinical trial, which will compare two strategies for the management of patients with stable coronary artery disease: routine invasive management with the intent to revascularize using contemporary PCI or CABG plus optimal medical therapy, versus routine optimal medical therapy alone, with cath reserved for refractory symptoms or an acute ischemic event. She was the Study Chair of the NHLBI funded Occluded Artery Trial (OAT), which tested the hypothesis that late opening of the infarct related artery (PCI/stent) will reduce the risk of death, MI and Class IV HF. Dr. Hochman previously demonstrated in an experimental model of myocardial infarction that late reperfusion reduced infarct expansion and adverse LV remodeling. She tested this hypothesis in a large clinical trial. 2201 stable patients with persistent total occlusion of the IRA were randomized to either routine PCI plus stenting and optimal medical therapy or optimal medical therapy alone, three days (minimum 24 hours) to 28 days after their MI. The initial results were presented at the American Heart Association 2006 Scientific Sessions and published in NEJM demonstrated that in stable MI survivors late recanalization of an occluded infarct-related vessel in the subacute phase does not improve outcome compared to optimal medical therapy alone. These findings led to a change in the national and European guidelines and as noted by many experts in the extensive press coverage, should change medical practice. The durability of those findings over the long- term (>6 years) was presented at the American Heart Association 2010 Scientific Sessions. In a subset of patients in the NHLBI funded angiographic ancillary study (TOSCA 2) less LV remodeling was seen with PCI. However, the NHLBI funded myocardial viability ancillary study did not confirm that and importantly, the presence of retained viability in the zone supplied by the infarct-related artery did not correlate with improvement in EF or LV size with PCI. In the initial report and long-term follow up results, assignment to PCI was associated with an adverse trend toward excess reinfarction in the PCI group. This excess was seen only for stent-related types of infarctions. She was the Study Chair of the NHLBI funded SHOCK Trial, which demonstrated a one year survival benefit for emergency PCI or CABG and led to a change in the national and European guidelines. She has investigated the role of systemic inflammation and excess nitric oxide in the genesis and persistence of cardiogenic shock and is Study Chair for phase 2 and phase 3 studies of nitric oxide synthase inhibition in refractory cardiogenic shock- SHOCK 2 and TRIUMPH. Dr. Hochman is on several steering committees for multi-center ACS trials including TRA 2P-Timi 50 trial (TRACER), SOLID-TIMI 52, ATLAS 2 ACS-TIMI 51, STABILITY, TRILOGY, and EARLY ACS.


  • Applying novel methods to assess clinical outcomes: insights from the TRILOGY ACS trial

    Bakal, Jeffrey A; Roe, Matthew T; Ohman, E Magnus; Goodman, Shaun G; Fox, Keith A A; Zheng, Yinggan; Westerhout, Cynthia M; Hochman, Judith S; Lokhnygina, Yuliya; Brown, Eileen B; Armstrong, Paul W
    European heart journal. 2015 Feb. 36 (6): 385-392

  • Standing the test of time [Editorial]

    Lala, Anuradha; Hochman, Judith S
    JACC: Heart failure. 2015 Mar. 3 (3): 243-244

  • Effects of timing, location and definition of reinfarction on mortality in patients with totally occluded infarct related arteries late after myocardial infarction

    Adlbrecht, Christopher; Huber, Kurt; Reynolds, Harmony R; Carvalho, Antonio C; Dzavik, Vladimir; Steg, Philippe Gabriel; Liu, Li; Marino, Paolo; Pearte, Camille A; Rankin, James M; White, Harvey D; Lamas, Gervasio A; Hochman, Judith S
    International journal of cardiology. 2014 Mar. 567-574.e12

Read All Publications (329)